FDA Approves MYCOPHENOLATE MOFETIL — CONCORD BIOTECH LIMITED

Concord Biotech Limited announced Thursday that its generic application (ANDA 210181) for Mycophenolate Mofetil – used to prevent organ transplant rejection – has been approved by the U.S. Food and Drug Administration, signaling the entry of a new generic into the immunosuppressant market. This approval enhances market competition for the brand name product, likely exerting pricing pressure and providing a fresh revenue stream for Concord Biotech in the managed care landscape.